DK1210951T3 - Præparat indeholdende östrogen-agonister/antagonister og testosteron til behandling af et fald i niveauet af hormonet testosteron - Google Patents

Præparat indeholdende östrogen-agonister/antagonister og testosteron til behandling af et fald i niveauet af hormonet testosteron

Info

Publication number
DK1210951T3
DK1210951T3 DK01309457T DK01309457T DK1210951T3 DK 1210951 T3 DK1210951 T3 DK 1210951T3 DK 01309457 T DK01309457 T DK 01309457T DK 01309457 T DK01309457 T DK 01309457T DK 1210951 T3 DK1210951 T3 DK 1210951T3
Authority
DK
Denmark
Prior art keywords
testosterone
antagonists
treat
decrease
level
Prior art date
Application number
DK01309457T
Other languages
English (en)
Inventor
David Burton Mclean
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1210951T3 publication Critical patent/DK1210951T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01309457T 2000-11-30 2001-11-08 Præparat indeholdende östrogen-agonister/antagonister og testosteron til behandling af et fald i niveauet af hormonet testosteron DK1210951T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25007100P 2000-11-30 2000-11-30
EP01309457A EP1210951B1 (en) 2000-11-30 2001-11-08 Composition containing estrogen agonists/antagonists and testosterone for treating a decline in the level of the hormone testosterone

Publications (1)

Publication Number Publication Date
DK1210951T3 true DK1210951T3 (da) 2005-03-29

Family

ID=22946195

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01309457T DK1210951T3 (da) 2000-11-30 2001-11-08 Præparat indeholdende östrogen-agonister/antagonister og testosteron til behandling af et fald i niveauet af hormonet testosteron

Country Status (15)

Country Link
US (2) US20020115676A1 (da)
EP (1) EP1210951B1 (da)
JP (1) JP2002193809A (da)
KR (1) KR20020042505A (da)
AT (1) ATE288303T1 (da)
AU (1) AU779964B2 (da)
CA (1) CA2363935A1 (da)
DE (1) DE60108710T2 (da)
DK (1) DK1210951T3 (da)
ES (1) ES2233570T3 (da)
HU (1) HUP0105201A3 (da)
IL (1) IL146701A0 (da)
NZ (1) NZ515822A (da)
PT (1) PT1210951E (da)
ZA (1) ZA200109836B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
EP1572178B1 (en) * 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
TWI330529B (en) * 2003-01-13 2010-09-21 Horphag Res Luxembourg Holding Sa A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof
MXPA05011896A (es) * 2003-05-05 2006-05-25 Univ Ben Gurion Preparaciones polimericas reticuladas inyectables y sus usos.
JP5069469B2 (ja) * 2003-12-15 2012-11-07 ラボラトワール ブザン アンテルナスィヨナル 女性化乳房治療用の薬剤を製造する際の４−ヒドロキシタモキシフェンの使用
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1550440A1 (en) * 2003-12-15 2005-07-06 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
US20090169520A1 (en) * 2004-01-09 2009-07-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, Pharmaceutical Compositions and Therapeutic Methods of Preventing and Treating Diseases and Disorders Associated With Amyloid Fibril Formation
US9572817B2 (en) 2008-07-04 2017-02-21 The Heart Research Institute Ltd. Use of androgens for vascular regeneration and endothelial repair
KR102335267B1 (ko) * 2017-03-16 2021-12-06 주식회사 자연과학기술 무지개송어 정소로부터 테스토스테론의 추출방법
EP4255439A4 (en) * 2020-12-04 2025-02-12 Lennham Pharmaceuticals, Inc. DEUTERATED FORMS OF TESTOSTERONE AND METHODS OF USE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US585905A (en) * 1897-07-06 Frank bonileor
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5589482A (en) * 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata

Also Published As

Publication number Publication date
HUP0105201A3 (en) 2004-04-28
US20050288325A1 (en) 2005-12-29
PT1210951E (pt) 2005-04-29
HU0105201D0 (en) 2002-01-28
AU779964B2 (en) 2005-02-24
US20020115676A1 (en) 2002-08-22
KR20020042505A (ko) 2002-06-05
JP2002193809A (ja) 2002-07-10
HUP0105201A2 (hu) 2002-12-28
EP1210951A3 (en) 2003-09-24
IL146701A0 (en) 2002-07-25
DE60108710D1 (de) 2005-03-10
DE60108710T2 (de) 2006-05-04
AU9516501A (en) 2002-06-06
ZA200109836B (en) 2003-05-29
EP1210951B1 (en) 2005-02-02
NZ515822A (en) 2003-05-30
ES2233570T3 (es) 2005-06-16
EP1210951A2 (en) 2002-06-05
ATE288303T1 (de) 2005-02-15
CA2363935A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
DK1199069T3 (da) Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed
MY136097A (en) Methods for treating osteoarthritis using an estrogen agonist/antagonist
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
CY1111049T1 (el) Συσκευη για αναμιξη και παροχη οστικου τσιμεντου
NO20024221D0 (no) Blandinger inneholdende alfa-2-adrenerge agonistkomponenter
TR199901669T2 (xx) Erkeklerdeki ereksiyon probleminin tedavisi i�in gerekli dozaj �ekilleri ve metod.
ATE354315T1 (de) Werkzeug zur stabilisierung von knochenstrukturen
DK1379224T3 (da) Guanylat-cyclase receptor-agonister til behandling af vævsinflammation og carciogenese
EE200300246A (et) EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
MXPA05006629A (es) Formas de dosificacion que contienen un inhibidor de bomba de protones, un nsaid y un amortiguador.
IS6388A (is) EP4 viðtaka valvís gerandefni í meðhöndluninni á beingisnun
DK1202724T3 (da) Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
IL146701A0 (en) Therapy for andropause using estrogen agonists/antagonists and testosterone
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
CL2004000026A1 (es) Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.
DE60336509D1 (de) Zubereitungen enthaltend sincalide
DK1272897T3 (da) Adenosin-A2A-receptorantagonister til behandling og forebyggelse af leverfibrose, cirrose og fedtlever
ATE248832T1 (de) Antagonisten des gonadotropin freisetzenden hormons
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
DK1467762T3 (da) Anvendelse af en H1-antagonist og rimexolon som et sikkert steroid til behandling af rhinitis
MXPA05011410A (es) Tratamiento de incontinencia con agonistas de 5htc2.
NO20034165L (no) Forankringshylse for injeksjonsfiksering
ATE373800T1 (de) Vorrichtung zur lichtmischung
EP1556069A4 (en) METHOD AND FORMULATIONS WITH AGONISTS AND ANTAGONISTS OF NUCLEAR HORMONE RECEPTORS
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling